@misc{oai:repo.qst.go.jp:00070834,
 author = {Karasawa, Kumiko and Matsumoto, Fumihiko and Ito, Shin and Oba, Shinichi and Furuya, Tomohisa and Hirowatari, Hisako and Izawa, Hiromi and Ito, Kana and Sasai, Keisuke and 唐澤 久美子},
 month = {Jul},
 note = {Purpose: To evaluate the value of hyperfractionated radiotherapy with concurrent use of low dose docetaxel in locally advanced head and neck cancer.
Methods: Patients eligible for this study had confirmed diagnosis of squamous cell carcinoma stages II (>10 m3), III, IVA and IVB of the head and neck. Radiotherapy was delivered twice a day at 1.2 Gy/fraction to a total dose of 72.0 Gy. Docetaxel (10 mg/m2) was administered weekly during radiotherapy.
Results: From March 2003 to October 2008, 70 patients were treated. Primary sites included the oropharynx (n=25), hypopharynx (n=24), larynx (n=18), and other sites (n= 3). Stages II (n=11), III (n=16), IVA (n=33) were included. Major grade 3 acute toxicities included mucositis (n=42) and treatment related pain (n=12). The median follow-up period for surviving patients was 43 months. The 2-year local control rate and overall survival rate were 72.5% and 70.0%, respectively.
Conclusion: Hyperfractionated radiotherapy with concurrent docetaxel is a valuable treatment modality for the management of locally advanced head and neck cancer., The 6th S. Takahashi Memorial Symposium & The 6th Japan-US Cancer Therapy International Joint Symposium},
 title = {Hyperfractionated radiotherapy with concurrent docetaxel in advanced head and neck cancer: a phase II study},
 year = {2012}
}